

Medical Biotechnology

Insulin - první gen biotech 1982

Recombinant proteins for human use


Table 10.1 Some recombinant proteins that have been approved for human use in either the United States or the European Union

| Compound | Company | Disorder |
|--|---|--|
| Factor VIII | Baxter Healthcare, Genetics Institute, Centeon, Bayer | Hemophilia A |
| Factor VIIa | Novo Nordisk | Some forms of hemophilia |
| Factor IX | Genetics Institute | Hemophilia B |
| Hirudin | Ciba Novartis, Europharm, Hoechst Marion Roussel | Venous thrombosis, heparin-associated thrombocytopenia |
| Tissue plasminogen activator | Genentech | Acute myocardial infarction |
| Truncated tissue plasminogen activator | Galenus Mannheim, Boehringer Mannheim/Centocor | Acute myocardial infarction |
| Insulin | Eli Lilly, Novo Nordisk, Hoechst AG | Diabetes mellitus |
| Insulin analogues | Eli Lilly, Novo Nordisk, Aventis | Diabetes mellitus |
| Human growth hormone | Eli Lilly, Genentech, Biotechnology General, Pharmacia, Upjohn, Novo Nordisk, Serono Laboratories | Growth hormone deficiency in children |
| Human growth hormone analogue | Genentech | Growth hormone deficiency in children |
| Human growth hormone | Serono Laboratories | AIDS-associated catabolism and wasting |
| Glucagon | Novo Nordisk | Hypoglycemia |
| Thyrotrophin- α | Genzyme | Thyroid cancer |
| Follicle-stimulating hormone | Ares-Serono, Organon | Anovulation and superovulation |
| Erythropoietin | Amgen, Ortho Biotech, Boehringer-Mannheim | Anemia |
| Platelet-derived growth factor | Ortho-McNeil Pharmaceuticals, Janssen-Cilag | Lower-extremity diabetic neuropathic ulcers |
| DNase I | Genentech | Cystic fibrosis |
| β -Glucocerebrosidase analogue | Genzyme | Gaucher disease |
| IFN- α_2 | Hoffmann-La Roche, Schering-Plough | Hairy cell leukemia, hepatitis B and C |
| Synthetic type 1 IFN- α | Amgen, Yamanouchi Europe | Chronic hepatitis C |
| IFN- α_{2b} | Schering-Plough | Hairy cell leukemia, genital warts, hepatitis B and C |
| IFN- β_{1b} analogues | Schering AG, Berlex Laboratories, Chiron | Multiple sclerosis |
| IFN- β_{1a} | Biogen, Ares-Serono | Relapsing multiple sclerosis |
| IFN- γ_{1b} | Genentech | Chronic granulomatous disease |
| IL-2 analogue | Chiron | Renal cell carcinoma |
| IL-11 analogue | Genetics Institute | Prevention of chemotherapy-induced thrombocytopenia |

Abbreviations: IFN, interferon; IL, interleukin.


- ~2003
- Approved in US or EU

Recombinant interferon: isolation of cDNA




- Strategies for isolating either the genes or cDNAs for human proteins
- 1) Isolate target protein and determine partial AAC sequence
 - Synthesize oligo as probe to screen cDNA library
- 2) Generate Ab against purified proteins
 - Screen gene library
- Interferon strategy above, **pre-human genome sequence**

Hybrid products: INF



- Interferons assist the immune response by **inhibiting viral replication** within host cells, activating natural killer cells, increasing antigen presentation to lymphocytes, and inducing the resistance of host cells to viral infection
- IFN cDNA isolated early 80s
- Now, three groups of IFN genes identified: α , β , γ
 - IFN α family of 13 genes; IFN β family of 2 genes; IFN γ of 1 genes
- IFN α_1 and α_2 have common RE sites
- Hybrid IFNs demonstrate potential therapeutics by combining functional domains
- Some (2003)- successful clinical trials, approved for use as human therapeutic agents

Site-specific directed mutagenesis: hGH



- hGH: 191 AAc, 22,1 kDa
 - One of first therapeutic proteins approved for human use
 - Recombinant form produced in *E. coli*, identical to native pituitary-derived hGH
 - Native binds to growth hormone receptor and prolactin receptor
- Side effects
- Prolactin receptor binding function of Zn⁺⁺ binding
 - Domain: His-18, His-21, Glu-174
- 2003, testing mutants

Optimizing gene expression

Table 10.2 Levels of interleukin-3 synthesis achieved in different host systems

| Host system | Promoter | Expression level (units) | Protein form |
|-------------------------|------------------------|--------------------------|-----------------|
| <i>B. licheniformis</i> | Amylase | 300 | 15 kDa (mature) |
| <i>E. coli</i> | <i>lacZ</i> | 500 | 20 kDa (fusion) |
| <i>E. coli</i> | <i>lacZ</i> | 20 | 15 kDa (mature) |
| Human cells | Metallothionein | 2 | 20–40 kDa |
| <i>K. lactis</i> | Lactase | 20 | 20–100 kDa |
| <i>S. cerevisiae</i> | Mating factor α | 20 | 20–100 kDa |

Adapted from van Leen et al., *BioTechnology* 9:47–52, 1991.


In each case, one of the strongest available promoters for that system was used.

- Multistep process:
 - Design a protein, construct a recombinant molecule, express and characterize
- Need to optimize expression
- First, either prokaryote or eukaryote host
 - Comparative analysis of host and expression
- ex., interleukin-3 expression
- Best in *Bacillus licheniformis*
- Balance with glycosylation in eukaryotic hosts
- But, glycosylation is not essential for interleukin-3 activity


Cystic fibrosis

| Mutation | Frequency worldwide |
|---------------|---------------------|
| $\Delta F508$ | 66.0% |
| G542X | 2.4% |
| G551D | 1.6% |
| N1303K | 1.3% |
| W1282X | 1.2% |

- Genetic disease affecting lungs and digestive system
- Average life span 37 years, extended and extending
- In US, ~1/3,900; 1/22 are carriers
- Most common in Europeans and Ashkenazi Jews
- Cystic fibrosis transmembrane conductance regulator (CFTR)
- Chloride ion channel, sweat, digestive juices and mucus
- thick, sticky mucus to build up in the lungs and digestive tract
- 7q31.2 → 180,000 bp gene, 1,480 AAC
- Most common mutation DF508; 1,400 other mutations
- DF508: missense, not folded correctly
- Lungs susceptible to bacterial infection
- Antibiotics treatment results in resistance and combination with DNA from bacteria and leukocytes causes pulmonary problems (mucus)



Treatment





- Genentech: hDNase I in CHO cells
- Not a cure, but alleviates symptoms
- Purified protein delivered via aerosol mist to lungs of CF
- Approved by FDA in 1994

Optimizing treatment




- Another symptom,
- In response to bacteria in lungs,
 - leukocytes cluster and lyse bacteria (and leukocytes)
 - Lysed leukocytes release actin
 - Monomeric actin binds DNase I very tightly and inhibits
 - Limits effectiveness
- X-ray structure data suggested Ala-144 required for binding or Tyr-65
- Changing either to Arg decreases actin binding by 10,000x
- Clinical efficacy of mutants to be determined (2003)

Clearing the lungs 2 with alginate lyase




- Alginate produced by seaweeds, soil and marine bacteria
- P. aeruginosa* excretion in lungs contributes to viscosity of mucus
- In addition to DNase I treatment, alginate lyase can be used as therapeutic agent

Cloning alginate lyase




Calcium
added



Alginate lyase
producer

- Flavobacterium sp.
- Clone bank in E. coli
- Screen by plating onto medium plus alginate
- +/- Ca⁺⁺
- Ca⁺⁺ + alginate = cross-linked opaque
- Hydrolyzed alginate does not cross-link
- Analysis and characterization of clones and alginate lyase

Alginate lyase[s]




- ORF 69,000 Da
- Precursor of three alginate lyases
- > 3,000 Da + 63,000 Da
- 63,000 Da lysates both bacterial and seaweed alginates
- 63,000 Da -> 23,000 Da seaweed effective+ 40,000 Da bacterial effective
- Clone bacterial activity portion

Optimization of activity



- Increase expression of 40,000 Da protein
- PCR amplify and insertion behind strong promoter
- *B. subtilis* plasmid, fused to a *B. subtilis* α-amylase leader peptide, directs secretion and penicillinase gene promoter
- Expressed and assayed for halo phenotype
- Liquifies alginates produced by *P. aeruginosa* isolated from lungs of CF patients
- 2003, additional trials to determine if effective therapeutic agent

Phenylketonuria treatment[s]



- Traditional treatment: diagnosis at birth or prenatal
- Controlled semi-synthetic diet with low levels of Phe
- Possible treatment: metabolism of Phe
 - PAH multienzyme complex, requiring cofactor
- Phe ammonia lyase (PAL) converts Phe as well
 - Stable and does not require cofactor
- To test concept, yPAL cloned and overexpressed in *E. coli*
 - Preclinical studies (2003) with mice deficient in PAL
 - See lower plasma levels of Phe when PAL injected or administered as oral encapsulated enzyme

Monoclonal antibodies (mAb) as therapeutic agents


Table 10.3 Some therapeutic monoclonal antibodies that have been approved for human use in either the United States or the European Union

| Date of approval | Type of antibody | Company | Therapeutic use |
|------------------|------------------|--|---|
| 1986 | Mouse | Ortho Biotech | Prevention of acute kidney transplant rejection |
| 1994 | Chimeric | Centocor | Prevention of blood clots |
| 1997 | Chimeric | Genentech, Idec Pharmaceuticals | Non-Hodgkin lymphoma |
| 1997 | Humanized | Protein Design Labs, Hoffmann-La Roche | Prevention of acute kidney transplant rejection |
| 1998 | Chimeric | Centocor, Schering-Plough | Crohn disease and rheumatoid arthritis |
| 1998 | Chimeric | Novartis | Prevention of acute kidney transplant rejection |
| 1998 | Humanized | Genentech | HER2-positive breast cancers |
| 1998 | Humanized | Medimmune | Respiratory syncytial virus infection in children |
| 1998 | Chimeric | Hoffmann-La Roche | Non-Hodgkin lymphoma |
| 2000 | Humanized | American Home Products, Celltech | Relapsed acute myeloid leukemia |
| 2001 | Humanized | Millennium Pharmaceuticals, Schering | Chronic lymphocytic leukemia |
| 2001 pending | Humanized | Genentech, Novartis, Tanox | Asthma |

In addition to the antibodies listed here, 11 have been approved for diagnostic purposes.


- Mouse mAb OKT3 first to be approved by FDA
- Immunosuppressive agent after organ transplant in humans

Antibody molecular structure




- CDRs variable portions of the protein, both H and L
- Fc elicits immunological responses after Ag-Ab
- Complement cascade

Polyclonal antibodies (Ab)



Monoclonal antibodies (mAb)



Monoclonal antibodies (theoretical)




FIGURE 2. Keeping the cells separated yields pure antibody: If the stimulated B lymphocytes can be kept separated and made to form antibody-secreting clones in separate cultures in vitro, we can harvest pure antibody. Compare with **Figure 1**.

Monoclonal antibodies (mAb) protocol




FIGURE 4. Schematic representation of the process of immortalizing an antibody-producing clone by hybridization, cloning, and selection of clones producing the desired antibodies.





FIGURE 1-4. Procedure for generating monoclonal antibodies

Herceptin[®]




- “Magic bullet”
- Genentech. FDA 9/98; Aullrich/Genentech and DSlamon/UCLA Jonsson Cancer Ctr
- Trastuzumab (trade name Herceptin)
- Humanized monoclonal antibody
- Target is HER2/neu receptor (erbB2)
- HER2-positive metastatic breast cancer
- Anti-cancer therapy in breast cancer, over-expressing erbB2 receptor
- ErbB2 receptor amplification occurs in 25-30% of early-stage breast cancers
- Transmembrane Tyr kinase, activating PI3K/Akt pathway and MAP pathway
- Overexpression promotes invasion, survival and angiogenesis of cells
- Also confers therapeutic resistance to cancer therapies
- Herceptin binds to extracellular domain of erbB2 receptor,
- Arresting cell at G1 phase

Magic bullet: delivery of drug to site



- Binding of mAb requires second step
- 1) delivery of drug
- 2) delivery of enzyme to convert pro-drug

Magic bullet: delivery of active agent to site



Monoclonal antibodies for cancer. ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment.[8]

- Binding of mAb requires second step
- variations

- Příklad ANTISENSE delivery

Human mAb problem




FIGURE 1-1 Antibody Structure and Functional Sites


Drawbacks to immunotherapeutic agents use

- Chemical couplings problem
 - Yields low; coupling at random sites; chemical portion may inactivate attached enzyme
- Nonhuman mAb
 - If condition requires multiple treatments, nonhuman mAb causes immune response

Human mAb


- Human chromosomes of fused human lymphocyte-mouse myeloma cells are unstable
- No human myeloma cell line can replace mouse myeloma cell line
- Ethics of injecting human subject to generate Ab-producing cells and doing partial splenectomy
- to collect Ab-producing cell

Hybrid human-mouse mAb: chimeric



- Genetic engineering to convert mouse mAb into a hybrid
- Exchange Fc portions
- Using oligonucleotides and in vitro DNA replication or cloned segments
- Construct in expression vector; transfect into cultured B lymphocytes
- Chimeric Abs are 70% human/30% mouse


Hybrid human-mouse mAb: chimeric



- Ex., chimera of mouse mAb against surface of human colon cancer cells
- Tested in patients with colorectal cancer
- Half-life in blood system 6x longer
- 1/10 patients developed mild response against chimera
- But, no anti-tumor activity observed (2003)
- Low dosage and/or advanced state of the cancer?


Jak je to delano

Hybrid human-mouse mAb: humanized




- Humanized Ab
- Substitute CDRs into human Ab
- 95 % human / 5 % mouse
- Construction by isolating cDNAs for L and H chains
- Amplify variable regions using PCR protocol
- Primers are complementary to ends of variable regions, conserved
- CDRs are highly variable sequences

PCR amplification of CDR




- Primers are hybrids, with
- 12 bases at ends corresponding to human mAb L chain cDNAs
- Six pairs of primers: 3 for V_L and 3 for V_H
- PCR protocol to splice these segments into human Ab, replacing CDRs
- 2003. 50 different mAbs have been humanized
- Technology is effective and widely applicable
- Time-consuming and expensive procedure

E. coli production of mAb: phage display




- Protocol for creating phage combinatorial libraries
- Hybridoma cells grow slowly, do not reach high cell densities, expensive to maintain
- Bioreactors: bacteria, plants and animals

DNA constructs of Fv combinatoral gene library



- Lambda phage
- Clones each L and H into two separate libraries
- Cut with common RE
- Directionally clone into third library: H -> L
- Combinations random
- RBS= ribosome binding site

Combinatorial library in M13



- PCR amplify V_H and V_L separately
- Add linker
- Ligate into M13 genome
- Displays on surface

Phage Display

Display peptide or protein on surface of bacterial virus
(in principle can use other viruses but phage viruses easiest to prepare etc.)
Some proteins on viral coats can accommodate peptides or proteins and will present them on the surface.

The phage genome (or alternatively phagemid) contains the sequence for the protein or peptide so isolation of the phage with desired phenotype will also provide the genotype.


Most popular is filamentous phage f1 or M13.

pIII on the end or pVIII along the length of the rod-like virion
for pVIII ~10% can be loaded with alternate peptide

Advantage of phage display: easy to screen over 10^9 sequences

Can either clone library directly into phage genome
or use a phagemid (plasmid that contains f1 ori) with replication deficient helper phage

Filamentous phage architecture



genIII protein, 42609 Da



genIX protein, 3650 Da



genVI protein, 12350 Da



genVII protein, 3600 Da




genVIII protein, 5240 Da



ssDNA, 6408 bp

5 copies of pIII and pVI 2800 copies pVIII - all can accommodate peptides



A library of phage, each displaying a different peptide sequence, is exposed to a plate coated with the target.


Unbound phage are washed away.

Specifically-bound phage are eluted with an excess of a known ligand for the target, or by lowering pH.

Eluted pool of phage is amplified, and the process is repeated for a total of 3 rounds.


After 3 rounds, individual clones are isolated and sequenced.

Combinatorial library in M13



- Assay expressed mAb by
- Immunological screening
- ELISA-like system
- Multiwell plate coated with target Ag
- Bind, wash
- Score with chromogenic substrate cleaved by Ab-enzyme complex

Shuffling CDR sequences




- Very large libraries yield wider range of Abs
- B cells from several non-immunized individuals collected and pooled
- mRNA isolated; cDNA synthesized
- PCR amplify all six CDR regions separately
- Pool with oligos encoding the framework regions and linker
- Overlap extension PCR gives variable L and H domains
- At 2×10^9 different single-chain Ab

Diagnosics

Using PCR to Detect for HIV

- **RT-PCR** (reverse transcriptase PCR).
- HIV has a ssRNA genome.
- Lyse plasma cells from the potentially infected person to release HIV RNA genome.
- The RNA is precipitated using isopropanol.
- Reverse transcriptase is used to make a **cDNA** copy of the RNA of the virus.
- This cDNA is used as a template to make **dsDNA**.

RT-PCR Diagnosis of HIV



Using PCR to Detect for HIV

- Specific primers are used to amplify a 156 bp portion of the HIV *gag* gene.
- Using standards the amount of PCR product can be used to determine the **viral load**.
- PCR can also be used as a prognostic tool to determine viral load.
- This method can also be used to determine the effectiveness antiviral therapy.

Gene polymorphism

Polymorphic refers to the existence of two or more forms of the same gene, or genetic marker

Each form must be too common in a population to be merely attributable to a new mutation


One type of polymorphism, **Single Nucleotide Polymorphisms (SNPs)**, can be used as a diagnostic tool

SNPs are the 3.2 million single nucleotide changes that differ between genomes

Most SNPs occur outside of genes, but some occur in gene promoters & a few occur in genes themselves

For SNPs to be useful, a person's DNA must be examined for the presence of specific SNPs

SNPs



Artwork by Jaanna Kelly © 2002

How do we identify SNPs?

DNA microarrays (DNA chips) make it possible to examine person for the presence of specific SNPs quickly and affordably

A single microarray can now be used to screen 100,000 SNPs found in a patient's genome in a matter of hours


How Are Microarrays Made?

Short fragments of DNA (oligonucleotides) corresponding to each version of all known SNPs are spotted onto a glass slide in a known order

A patient's DNA is fragmented and each fragment is linked to a fluorescent dye

This pool of fragments is allowed to hybridize to its corresponding oligonucleotide on the chip

The pattern of fluorescence determines which SNPs are found in the patient



Whole Human Genome Microarray by Agilent Technologies

1" x 3" glass slide with 44,000 genes dotted




What Can SNPs Be Used to Predict?


A person's susceptibility to disease is linked to which alleles they carry as well as how those alleles interact with the environment

SNPs can be used to build a profile of a person's susceptibility to various diseases

Example:

Craig Venter (Celera genomics) has an increased risk of heart attack based on a SNP in the promoter of the MMP-3 gene





Adapted by Jeanne Kelly © 2008

Drug Dosing/Reaction

Average patient

There is no simple way to determine how particular patient will respond to a medication


Adverse Drug Reactions (ADRs) one of the important causes of hospitalization and death in the United States

Medical drugs are developed using a “average” patient

Pharmacogenomics examines the DNA variations that is correlated to drug response

Can be used to predict if a patient will have a good response to a drug, a bad response to a drug, or no response at all


Human chromosome #8



(a)



Hypothetical SNP map of "typical" patient who responds well to drug being tested.






Hypothetical SNP map of "typical" patient who exhibits severe adverse response to the drug.



SNP's correlated with positive drug response.

Key: =A =G =C =T

(b)



Adapted by Juana Kelly © 2008

Testing for Variation

Cytochrome p450 (CYP450) involved in drug metabolism
Four major types; CYP3A, CYP2C9, CYP2D6 & CYP2C19

Variations in at least 3 genes regulate drug metabolism

By looking at the alleles a person has of these genes it is possible to predict how a patient will react to a drug

Dosing can be regulated so that a patient gets the maximum benefit without possible toxic side effects

CYP Genes & Their Metabolites

CYP3A

Antihistamines

Statins

Ca⁺ Channel Blockers

Benzodiazepines

HIV protease inhibitors

CYP2D6

Codeine

Beta-Blockers

Tricyclic Antidepressants

Tamoxifen

CYP2C9

NSAIDs

Anti-epileptics

Warfarin

CYP2C19 (Missing in 30% of Asians)

Proton pump inhibitors

Valium

Herceptin targets HER2 & is effective in stopping breast cancer growth

Only 25 to 30% of breast cancers overexpress HER2

Erbbitux effective in colorectal cancers by stopping signaling through EGFR


Not all colorectal cancers overexpress EGFR

Diagnostic tests are used to detect which tumors will benefit from treatment allowing better use of treatment time & money

Tumors Are Not Identical So Why Should Every Patient be Treated the Same?

Red = gene induction


Green = gene repression




1733 Genes

84 breast tumor samples

Recombinant DNA Drugs



Chinese Hamster Ovary Cells



Most popular cells for producing proteins that are not able to be produced in *E. coli*

These are proteins that are difficult to fold, glycosylated, or even toxic to the bacteria

Mammalian Cell Bioreactor



Protein Drugs Made in CHO Cells

Avonex (Interferon Beta-1a) Multiple Sclerosis - Biogen

Herceptin (Trastuzumab) Breast Cancer - Genentech

Humira (Adalimumab) Rheumatoid Arthritis - Abbott Labs

Remicade (Infliximab) Crohn's Disease - Centocor

Embrel (Etanercept) Rheumatoid Arthritis - Amgen



GENE THERAPY

Gene Therapy

Cells are removed from a patient and modified either by having a working copy of a defective gene inserted or a therapeutic gene added

Once the cells are expressing the new gene correctly, they are inserted back into the patient (*ex vivo*)


The gene is usually delivered using a **defective virus**

Sometimes the virus is delivered directly into the patient (*in vivo*)

Jak je to delano,

priklady, doplnit

Gene Therapy



Gene-Therapy and SCIDs

Severe Combined Immune Deficiency (SCID): no T cells

Two types: ADA-SCID & SCID-X1

>20 SCID patients have been successfully treated

The FDA has not approved any human gene therapy

Current State of Gene Therapy

Little progress has been made since the first gene therapy clinical trials begun in 1990

In 1999, gene therapy suffered a major setback with the death of 18-year-old Jesse Gelsinger

Part of a gene therapy trial for **ornithine transcarboxylase deficiency (OTCD)**

Died from multiple organ failures 4 days post-treatment

Death was caused by a severe immune response

In 2003, the FDA placed a temporary halt on all gene therapy trials using retroviral vectors in blood stem cells

FDA took this action after it learned that two children treated in a French gene therapy trial had developed a leukemia-like condition

These children in August 2002 had been successfully treated by gene therapy (SCID-X1)

Stem Cells

Stem cells are unspecialized cells that renew themselves for long periods through cell division.

Under certain physiologic or experimental conditions, they can be induced to become cells with special functions such as the beating cells of the heart muscle or the insulin-producing cells of the pancreas

These cells could then be used to repair or replace damaged organs or tissues

Three Types of Stem Cells

- Embryonic
- Adult/Somatic
- Induced Pluripotent

Human Embryonic Stem Cells

In 1998, **human embryonic stem cells** (hES) were isolated and grown in the laboratory


hES cells are derived from the ICM of human blastocysts

These cells are **pluripotent** just like mouse ES cells

The embryos used in these studies were created for infertility purposes through *in vitro* fertilization

They were donated for research with the informed consent of the donor

Pluripotent Stem Cells



Therapeutic Cloning

Isolation of cloned cells/tissue for curing disease or injury


The nucleus from an adult cell is placed in an enucleated egg

Instead of implanting the egg and letting it grow into a fetus, it is cultured until the blastocyst stage where ES cells are removed and cultured

These ES cells are coaxed down a specific developmental pathway such that they differentiate into a specific tissue

This allows for the creation of cells identical to the donor thus preventing rejection

Human Therapeutic Cloning



Adult Stem Cells

An **adult** or **somatic stem cell** is an undifferentiated cell found among differentiated cells in a tissue or organ

It can renew itself, and can differentiate to yield the major specialized cell types of the tissue or organ

The primary roles of adult stem cells are to maintain and repair the tissue in which they are found

These cells are more restricted as to what cell types they can become & are thus said to be **multipotent**

1960s, two stem cell populations identified in bone marrow


One population, called **hematopoietic stem cells**, forms all the types of blood cells in the body

The second, called **mesenchymal stem cells** generate bone, cartilage, fat, & connective tissue

Hematopoietic stem cells have also been isolated from umbilical cord blood

Mesenchymal stem cells have now been isolated from amniotic fluid, umbilical cord blood, and adipose tissue


Bone Marrow Stem Cells




Tissue Engineering

Tissue engineering or **regenerative medicine** is a multidisciplinary field combining biology, medicine, and engineering & involving the restoration, maintenance, or enhancement tissue & organ function

Often involves the growth of new tissue or organs within a 3D matrix to mimic natural organ growth




Generation of Replacement Knee Cartilage



Valvular heart disease is a major cause of mortality

Currently available substitutes for failing heart valves have serious limitations

An alternative is to tissue engineer heart valves




Engineering a Blood Vessel


A California company can create blood vessels in the lab using the patient's own cells.



HARVEST A small piece of skin the size of a postage stamp is removed from the back of the patient's hand. Skin cells from the biopsy are isolated and placed in a culture dish.



GROWTH Over several weeks, the skin cells grow into a thin sheet.



CONSTRUCTION The sheet is rolled onto a metal cylinder and placed in a serum. After eight weeks the cylinder is removed, and the tube of cells is seeded with cells from the lining of the patient's veins.



FINISH After several weeks the vein cells have lined the tube, and the vessel is ready for implanting.

Source: *Cytograft*

THE NEW YORK TIMES

Cartilage scaffold of a human ear implanted under the skin of a mouse

